Protagonist Therapeutics, Inc insider trading
PTGXfinancial statementsForm 4 filings on EDGAR145 transactions since Nov 9, 2024
From August 12, 2026 to November 9, 2026, 0 insiders at Protagonist Therapeutics, Inc bought $0 of stock in the open market, and 2 sold $27M. Officers and directors accounted for $0 of purchases and $27M of sales. The last reported transaction was an option exercise by Ali Asif on September 30, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through October 2, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $27MAug 12, 2026 – Nov 9, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Nov 6, 2026. Insider data through Nov 9, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
145 transactions from November 9, 2024 to November 9, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Ali Asif | Chief Financial Officer | option exercise | 9,229 | $38.98 | $360K | 68,232 | Oct 2, 2026 |
| Sep 30, 2026 | Ali Asif | Chief Financial Officer | option exercise | 28,438 | $23.42 | $666K | 96,670 | Oct 2, 2026 |
| Sep 30, 2026 | Ali Asif | Chief Financial Officer | option exercise | 15,650 | $19.19 | $300K | 112,320 | Oct 2, 2026 |
| Sep 30, 2026 | Ali Asif | Chief Financial Officer | option exercise | 5,312 | $12.17 | $65K | 117,632 | Oct 2, 2026 |
| Sep 30, 2026 | Ali Asif | Chief Financial Officer | open-market sale10b5-1 | 12,595 | $141.77 | $2M | 105,037 | Oct 2, 2026 |
| Sep 30, 2026 | Ali Asif | Chief Financial Officer | open-market sale10b5-1 | 46,034 | $141.78 | $7M | 59,003 | Oct 2, 2026 |
| Sep 10, 2026 | Patel Dinesh V PH D | President and CEO, Director | option exercise | 7,278 | $21.58 | $157K | 530,246 | Sep 10, 2026 |
| Sep 10, 2026 | Patel Dinesh V PH D | President and CEO, Director | open-market sale10b5-1 | 7,278 | $144.10 | $1M | 522,968 | Sep 10, 2026 |
| Sep 9, 2026 | Patel Dinesh V PH D | President and CEO, Director | option exercise | 63,548 | $21.58 | $1M | 586,516 | Sep 10, 2026 |
| Sep 9, 2026 | Patel Dinesh V PH D | President and CEO, Director | open-market sale10b5-1 | 63,548 | $146.18 | $9M | 522,968 | Sep 10, 2026 |
| Sep 8, 2026 | Patel Dinesh V PH D | President and CEO, Director | option exercise | 54,174 | $21.58 | $1M | 577,142 | Sep 10, 2026 |
| Sep 8, 2026 | Patel Dinesh V PH D | President and CEO, Director | open-market sale10b5-1 | 54,174 | $145.87 | $8M | 522,968 | Sep 10, 2026 |
| Sep 3, 2026 | Patel Dinesh V PH D | President and CEO, Director | gift | 510 | $0.00 | — | 522,968 | Sep 8, 2026 |
| Aug 11, 2026 | Patel Dinesh V PH D | President and CEO, Director | option exercise | 34,239 | $21.58 | $739K | 557,717 | Aug 12, 2026 |
| Aug 11, 2026 | Patel Dinesh V PH D | President and CEO, Director | open-market sale10b5-1 | 34,239 | $148.52 | $5M | 523,478 | Aug 12, 2026 |
| Aug 10, 2026 | Patel Dinesh V PH D | President and CEO, Director | option exercise | 65,761 | $21.58 | $1M | 589,239 | Aug 12, 2026 |
| Aug 10, 2026 | Patel Dinesh V PH D | President and CEO, Director | open-market sale10b5-1 | 65,761 | $149.11 | $10M | 523,478 | Aug 12, 2026 |
| Jun 23, 2026 | Waddill William D. | Director | option exercise | 9,000 | $16.54 | $149K | 16,825 | Jun 25, 2026 |
| Jun 23, 2026 | Waddill William D. | Director | open-market sale10b5-1 | 9,000 | $117.94 | $1M | 7,825 | Jun 25, 2026 |
| Jun 10, 2026 | Waddill William D. | Director | option exercise | 3,000 | $11.80 | $35K | 10,825 | Jun 11, 2026 |
| Jun 10, 2026 | Waddill William D. | Director | option exercise | 6,000 | $16.54 | $99K | 16,825 | Jun 11, 2026 |
| Jun 10, 2026 | Waddill William D. | Director | open-market sale10b5-1 | 9,000 | $107.68 | $969K | 7,825 | Jun 11, 2026 |
| May 29, 2026 | Waddill William D. | Director | option exercise | 9,000 | $11.80 | $106K | 16,825 | Jun 1, 2026 |
| May 29, 2026 | Waddill William D. | Director | open-market sale10b5-1 | 9,000 | $99.64 | $897K | 7,825 | Jun 1, 2026 |
| May 12, 2026 | Patel Dinesh V PH D | President and CEO, Director | option exercise | 75,000 | $21.58 | $2M | 598,478 | May 14, 2026 |
| May 12, 2026 | Patel Dinesh V PH D | President and CEO, Director | open-market sale10b5-1 | 75,000 | $100.12 | $8M | 523,478 | May 14, 2026 |
| May 12, 2026 | Patel Dinesh V PH D | President and CEO, Director | option exercise | 75,000 | $21.58 | $2M | 598,478 | May 12, 2026 |
| May 12, 2026 | Patel Dinesh V PH D | President and CEO, Director | open-market sale | 75,000 | $100.12 | $8M | 523,478 | May 12, 2026 |
| May 8, 2026 | Giraudo Bryan | Director | open-market saleindirect | 6,000 | $100.00 | $600K | 0 | May 11, 2026 |
| May 8, 2026 | Giraudo Bryan | Director | open-market sale | 5,130 | $100.00 | $513K | 12,695 | May 11, 2026 |
| May 7, 2026 | Giraudo Bryan | Director | option exercise | 24,000 | $6.45 | $155K | 31,825 | May 11, 2026 |
| May 7, 2026 | Giraudo Bryan | Director | option exercise | 12,000 | $6.98 | $84K | 43,825 | May 11, 2026 |
| May 7, 2026 | Giraudo Bryan | Director | open-market sale | 36,000 | $100.14 | $4M | 27,825 | May 11, 2026 |
| May 7, 2026 | Giraudo Bryan | Director | open-market saleindirect | 12,000 | $100.07 | $1M | 6,000 | May 11, 2026 |
| Apr 23, 2026 | Patel Dinesh V PH D | President and CEO, Director | gift | 1,460 | $0.00 | — | 523,478 | Apr 24, 2026 |
| Apr 20, 2026 | Ali Asif | Chief Financial Officer | open-market sale | 1,750 | $105.47 | $185K | 59,003 | Apr 21, 2026 |
| Mar 26, 2026 | Molina Arturo MD | Chief Medical Officer | open-market sale | 15,000 | $104.79 | $2M | 84,115 | Mar 27, 2026 |
| Mar 26, 2026 | Molina Arturo MD | Chief Medical Officer | option exercise | 15,000 | $8.04 | $121K | 99,115 | Mar 27, 2026 |
| Mar 26, 2026 | Selick Harold E | Director | open-market sale | 24,000 | $105.00 | $3M | 60,845 | Mar 27, 2026 |
| Mar 26, 2026 | Selick Harold E | Director | option exercise | 24,000 | $12.88 | $309K | 84,845 | Mar 27, 2026 |
| Mar 26, 2026 | Ali Asif | Chief Financial Officer | open-market sale | 24,765 | $104.24 | $3M | 60,753 | Mar 27, 2026 |
| Mar 26, 2026 | Ali Asif | Chief Financial Officer | option exercise | 5,265 | $12.17 | $64K | 85,518 | Mar 27, 2026 |
| Mar 26, 2026 | Ali Asif | Chief Financial Officer | option exercise | 19,500 | $19.19 | $374K | 80,253 | Mar 27, 2026 |
| Mar 25, 2026 | Patel Dinesh V PH D | President and CEO, Director | open-market sale | 54,641 | $101.00 | $6M | 524,938 | Mar 25, 2026 |
| Mar 25, 2026 | Patel Dinesh V PH D | President and CEO, Director | option exercise | 54,641 | $8.58 | $469K | 579,579 | Mar 25, 2026 |
| Mar 24, 2026 | Patel Dinesh V PH D | President and CEO, Director | option exercise | 59 | $8.58 | $506 | 524,997 | Mar 25, 2026 |
| Mar 24, 2026 | Patel Dinesh V PH D | President and CEO, Director | open-market sale | 59 | $101.00 | $6K | 524,938 | Mar 25, 2026 |
| Mar 23, 2026 | Patel Dinesh V PH D | President and CEO, Director | gift | 50,000 | $0.00 | — | 524,938 | Mar 25, 2026 |
| Feb 17, 2026 | Williams Lewis T | Director | option exercise | 18,000 | $10.84 | $195K | 25,825 | Feb 18, 2026 |
| Feb 17, 2026 | Williams Lewis T | Director | open-market sale | 18,000 | $82.42 | $1M | 7,825 | Feb 18, 2026 |
Who the insiders are
Everyone who reported a transaction since November 9, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Patel Dinesh V PH D | President and CEO, Director | Sep 10, 2026 | option exercise | 530,246 | — | $61M (14) | 6 of 14 |
| Ali Asif | Chief Financial Officer | Sep 30, 2026 | option exercise | 68,232 | — | $16M (7) | 2 of 7 |
| Giraudo Bryan | Director | May 8, 2026 | open-market sale | 12,695 | — | $6M (4) | 0 of 4 |
| Waddill William D. | Director | Jun 23, 2026 | option exercise | 16,825 | — | $5M (4) | 3 of 4 |
| Molina Arturo MD | Chief Medical Officer | Mar 26, 2026 | open-market sale | 84,115 | — | $4M (6) | 0 of 6 |
| Selick Harold E | Director | Mar 26, 2026 | open-market sale | 60,845 | — | $3M (1) | 0 of 1 |
| Williams Lewis T | Director | Feb 17, 2026 | option exercise | 25,825 | — | $1M (1) | 0 of 1 |
| Gupta Suneel | Chief Development Officer | Nov 26, 2024 | open-market sale | 266,983 | — | — | — |
| O'Dowd Sarah A | Director | Jan 2, 2026 | award | 7,825 | — | — | — |
Questions
Are Protagonist Therapeutics, Inc insiders buying or selling?
Over the twelve months to November 9, 2026, 7 insiders at Protagonist Therapeutics, Inc sold $95M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $95M. Only open-market purchases and sales are counted.
Who sold the most Protagonist Therapeutics, Inc stock in the last year?
Patel Dinesh V PH D (President and CEO, Director) sold $61M in 14 open-market sales over the twelve months to November 9, 2026.
Do Protagonist Therapeutics, Inc executives sell under 10b5-1 plans?
11 of the 37 open-market sales in the last twelve months (30%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Protagonist Therapeutics, Inc
- Protagonist Therapeutics, Inc financial statements
- 2 tracked funds holding PTGX
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.